Show source-provided references
1. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: Recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
10.1111/ane.12667 ↗5. Structured Reporting in Multiple Sclerosis—Consensus-Based Reporting Templates for Magnetic Resonance Imaging of the Brain and Spinal Cord
10.1055/a-1867-3942 ↗6. Radiologist Preferences, Agreement, and Variability in Phrases Used to Convey Diagnostic Certainty in Radiology Reports
10.1016/j.jacr.2018.09.052 ↗9. Do MRI Structured Reports for Multiple Sclerosis Contain Adequate Information for Clinical Decision Making?
10.2214/AJR.17.18451 ↗12. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
10.1177/1352458518814117 ↗13. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque
10.1002/ana.24497 ↗17. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
10.1093/brain/awz212 ↗18. Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients
10.1177/1352458520974357 ↗20. Honce, J.M., Nair, K.V., Hoyt, B.D., Seale, R.A., Sillau, S., Engebretson, E., Schurr, B., Corboy, J.R., Vollmer, T.L., and Alvarez, E. (2020). Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front. Neurol., 11.
10.3389/fneur.2020.01045 ↗21. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis
10.1177/1352458515616701 ↗22. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
10.1002/ana.24018 ↗24. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
10.1093/brain/awv398 ↗25. Stratification of multiple sclerosis patients using unsupervised machine learning: A single-visit MRI-driven approach
10.1007/s00330-022-08610-z ↗26. Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5-year study
10.1002/hbm.23755 ↗27. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant
10.1093/brain/awv337 ↗28. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study
10.3174/ajnr.A5915 ↗29. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease
10.1002/ana.25150 ↗30. Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis
10.1002/ana.26281 ↗31. Hänninen, K., Viitala, M., Paavilainen, T., Karhu, J.O., Rinne, J., Koikkalainen, J., Lötjönen, J., and Soilu-Hänninen, M. (2019). Thalamic Atrophy Without Whole Brain Atrophy Is Associated with Absence of 2-Year NEDA in Multiple Sclerosis. Front. Neurol., 10.
10.3389/fneur.2019.00459 ↗32. A matter of atrophy: Differential impact of brain and spine damage on disability worsening in multiple sclerosis
10.1007/s00415-021-10576-9 ↗36. Inglese, M., Petracca, M., Mormina, E., Achiron, A., Straus-Farber, R., Miron, S., Fabian, M., Krieger, S., Miller, A., and Lublin, F. (2017). Cerebellar volume as imaging outcome in pro-gressive multiple sclerosis. PLoS ONE, 12.
10.1371/journal.pone.0176519 ↗37. Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trial
10.1111/ene.15157 ↗40. Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review
10.1007/s00234-021-02746-3 ↗